Replies to post #10923 on Titan Pharmaceuticals Inc (TTNP)

[KMBJN]

Amazing how much Braeburn has going on.

D3 antagonism / partial agonist they might be granted I believe they are only planning on using for "opioid use disorder, schizophrenia, bipolar disorder, and tetrahydrocannabinol dependence," but not Parkinson's disease.

I don't think the D3 antagonist / partial agonist will be useful for treating Parkinson's disease, which responds more to dopamine D2 receptor activation.

There's a lot of D3 receptors in nucleus accumbens, so shutting off this reward center may help dull the reinforcing stimulus of opioids and THC? D3 receptor antagonism may lead to motivational deficits. Some interesting papers about D3 receptors:

Motivation in mouse PD model:
http://www.nature.com/tp/journal/v4/n6/full/tp201443a.html

D3 antagonism in addiction:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148950/

D3 antagonism for neurological diseases:
http://journal.frontiersin.org/article/10.3389/fnins.2016.00451/pdf

D3 receptors in cognition:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748034/